BELL vs. AVO, RUA, MHC, SUN, DEMG, NIOX, SN, MXCT, EKF, and IUG
Should you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), MyHealthChecked (MHC), Surgical Innovations Group (SUN), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), MaxCyte (MXCT), EKF Diagnostics (EKF), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical devices" industry.
Belluscura vs.
Belluscura (LON:BELL) and Advanced Oncotherapy (LON:AVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Advanced Oncotherapy has a net margin of 0.00% compared to Belluscura's net margin of -1,030.73%. Advanced Oncotherapy's return on equity of -67.34% beat Belluscura's return on equity.
Belluscura has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Advanced Oncotherapy has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500.
Advanced Oncotherapy received 189 more outperform votes than Belluscura when rated by MarketBeat users.
Belluscura has higher revenue and earnings than Advanced Oncotherapy. Belluscura is trading at a lower price-to-earnings ratio than Advanced Oncotherapy, indicating that it is currently the more affordable of the two stocks.
In the previous week, Belluscura's average media sentiment score of 0.00 equaled Advanced Oncotherapy'saverage media sentiment score.
6.3% of Belluscura shares are owned by institutional investors. Comparatively, 17.8% of Advanced Oncotherapy shares are owned by institutional investors. 56.3% of Belluscura shares are owned by company insiders. Comparatively, 47.5% of Advanced Oncotherapy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Advanced Oncotherapy beats Belluscura on 6 of the 11 factors compared between the two stocks.
Get Belluscura News Delivered to You Automatically
Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belluscura Competitors List
Related Companies and Tools
This page (LON:BELL) was last updated on 5/22/2025 by MarketBeat.com Staff
